Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.

ERS issues new bronchiectasis guidelines to improve patient care, standardise treatment, and reduce variability in global ...

During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), has endorsed two ...

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

The EMA recommendation comes after a phase 3 randomized, double-blind, placebo-controlled clinical trial which involved 1721 patients aged 12 and older. Patients were treated with either 10 mg or 25 ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, ...

A bronchiectasis action management plan for children significantly improved flu vaccine uptake but not the level of unscheduled doctor visits.

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

SINCE Laennec 1 first described and named bronchiectasis its etiology and mode of development have been controversial issues. Numerous theories have been advanced, each of which is backed by ...

Tactile Systems Technology's fair value has remained steady at $16.83, even as its discount rate saw a slight uptick this period. Analysts attribute these developments to a balance between the company ...